Agilent Technologies, Inc. (NYSE:A) CEO Michael R. Mcmullen sold 16,492 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $65.33, for a total value of $1,077,422.36. Following the completion of the sale, the chief executive officer now directly owns 211,872 shares in the company, valued at $13,841,597.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Agilent Technologies, Inc. (NYSE A) traded up 0.43% during midday trading on Friday, hitting $65.96. The company had a trading volume of 2,295,974 shares. The company’s 50 day moving average is $62.22 and its 200 day moving average is $57.91. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $66.42. The firm has a market cap of $21.23 billion, a price-to-earnings ratio of 34.02 and a beta of 1.30.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.07. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.49 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post $2.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) CEO Michael R. Mcmullen Sells 16,492 Shares” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/15/agilent-technologies-inc-a-ceo-michael-r-mcmullen-sells-16492-shares.html.

Several hedge funds and other institutional investors have recently bought and sold shares of A. Balentine LLC lifted its position in shares of Agilent Technologies by 2.9% during the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after purchasing an additional 50 shares during the last quarter. Sun Life Financial INC lifted its position in shares of Agilent Technologies by 26,144.4% during the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after purchasing an additional 2,353 shares during the last quarter. Acrospire Investment Management LLC lifted its position in shares of Agilent Technologies by 92.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after purchasing an additional 1,200 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Agilent Technologies by 5.3% during the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after purchasing an additional 131 shares during the last quarter. Finally, Trust Co. of Vermont lifted its position in shares of Agilent Technologies by 1.8% during the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after purchasing an additional 50 shares during the last quarter.

A has been the topic of a number of research reports. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Janney Montgomery Scott raised their price objective on Agilent Technologies from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, August 16th. J P Morgan Chase & Co restated an “overweight” rating and issued a $70.00 price objective on shares of Agilent Technologies in a report on Wednesday, August 16th. Bank of America Corporation raised their price objective on Agilent Technologies from $66.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 16th. Finally, Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a report on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $63.91.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.